| 3.11 0.44 (16.48%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.93 |
1-year : | 4.59 |
| Resists | First : | 3.36 |
Second : | 3.93 |
| Pivot price | 2.2 |
|||
| Supports | First : | 2.39 |
Second : | 1.78 |
| MAs | MA(5) : | 2.59 |
MA(20) : | 2.15 |
| MA(100) : | 2.01 |
MA(250) : | 1.49 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 85.3 |
D(3) : | 80.7 |
| RSI | RSI(14): 72.4 |
|||
| 52-week | High : | 3.36 | Low : | 0.69 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ APLT ] has closed It is unclear right now based on current values. 85% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.37 - 3.38 | 3.38 - 3.39 |
| Low: | 2.54 - 2.56 | 2.56 - 2.57 |
| Close: | 3.09 - 3.11 | 3.11 - 3.13 |
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Fri, 08 Dec 2023
Where Does Applied Therapeutics Inc (APLT) Stock Fall in the Biotechnology Field After It Has Risen 26.45% This Week? - InvestorsObserver
Fri, 08 Dec 2023
Stacy Kanter Bought 167% More Shares In Applied Therapeutics - Simply Wall St
Thu, 07 Dec 2023
Is Applied Therapeutics Inc (APLT) Stock About to Get Hot Thursday? - InvestorsObserver
Thu, 30 Nov 2023
Is Applied Therapeutics Inc (APLT) Stock a Smart Value Thursday? - InvestorsObserver
Mon, 27 Nov 2023
Does Applied Therapeutics Inc (APLT) Have What it Takes to be in Your Portfolio Monday? - InvestorsObserver
Thu, 09 Nov 2023
Applied Therapeutics Inc (APLT) Reports Q3 2023 Financial Results Amidst Upcoming Clinical ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 77 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 10.1 (%) |
| Held by Institutions | 74.5 (%) |
| Shares Short | 1,980 (K) |
| Shares Short P.Month | 1,520 (K) |
| EPS | -1.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.15 |
| Profit Margin | 0 % |
| Operating Margin | -586.3 % |
| Return on Assets (ttm) | -76.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.13 |
| EBITDA (p.s.) | -0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -54 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -2.49 |
| PEG Ratio | 0 |
| Price to Book value | -22.22 |
| Price to Sales | 22.53 |
| Price to Cash Flow | -4.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|